Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference
Silverback Therapeutics (Nasdaq: SBTX) announced its participation in the Goldman Sachs 42nd Annual Global Healthcare Conference. The event will feature a fireside chat with CEO Laura Shawver, Ph.D., and President Valerie Odegard, Ph.D., scheduled for June 8, 2021, at 3:50 p.m. ET. The live webcast will be accessible on Silverback’s investor relations website, with a replay available for 30 days. Silverback focuses on developing targeted therapeutics for cancer and other diseases using its proprietary ImmunoTAC technology platform.
- None.
- None.
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the Goldman Sachs 42nd Annual Global Healthcare Conference.
Laura Shawver, Ph.D., Chief Executive Officer, and Valerie Odegard, Ph.D., President and Chief Scientific Officer, will represent Silverback at a fireside chat on Tuesday, June 8th, 2021 at 3:50 p.m. ET / 12:50 p.m. PT. The live webcast of the fireside chat will be available on Silverback’s investor relations website and a replay will be available for 30 days following the event. Members of the Silverback management team will also host investor meetings during the conference.
About Silverback Therapeutics
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210601005033/en/
FAQ
What is Silverback Therapeutics participating in on June 8, 2021?
Who will represent Silverback at the Goldman Sachs conference?
What time is the fireside chat at the Goldman Sachs conference?
Where can I watch the Silverback Therapeutics fireside chat?
What is the focus of Silverback Therapeutics?
